Novartis

SANDOSTATIN LAR DEPOT

Manufacturer:

Novartis

Sandostatin Lar Depot HCPCS:

J2353

HCPCS Code Descriptor:

Injection, octreotide, depot form for intramuscular injection, 1 mg

Category:

J Code

Sandostatin Lar Depot NDCs:

00078-0804-61, 00078-0825-81, 00078-0797-61, 00078-0818-81, 00078-0811-81, 00078-0790-61

Primary Type:

Growth Disorder

Generic/Specialty Status:

Single-Source

Route of Administration:

Intramuscular

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

00078-0804-61, 00078-0797-61, 00078-0790-61

About Sandostatin Lar Depot:

SANDOSTATIN LAR DEPOT is a Growth Disorder drug manufactured by Novartis and administered via the Intramuscular route of administration. The J Code: J2353 is aligned to the drug SANDOSTATIN LAR DEPOT.

ACCESS PRICING AND MORE BY REGISTERING

J2353 Added Date:

January 1, 2004

J2353 Effective Date:

January 1, 2004

J2353 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Sandostatin Lar Depot billing and coding information.
Sandostatin Lar Depot patient assistance information can be found through Novartis Patient Support at the URL: https://www.hcp.novartis.com/products/sandostatin-lar-depot/carcinoid-syndrome/access/
SANDOSTATIN LAR DEPOT prescribing information can be found at the link below:
Information regarding SANDOSTATIN LAR DEPOT’s side effects can be found at MedlinePlus